The first-in-human trial of JANX007 will be carried out in metastatic castration-resistant prostate cancer (mCRPC) patients.
Dosing of the first patient with this therapy was carried out at the Sarah Cannon Research Institute (SCRI).
The open-label, multi-centre, dose escalation trial has been designed for assessing ascending doses of the therapy in mCRPC patients.
In this trial, the tolerability, safety, pharmacokinetic, pharmacodynamic, and the initial efficacy of JANX007 will be evaluated as a monotherapy in adults with mCRPC.
Janux Therapeutics chief medical officer Wayne Godfrey said: “We are excited to begin clinical evaluation of our first product candidate.
“Importantly, JANX007 has the potential for tumour-selective T cell activation and tumour cell killing.
“Preclinical data have shown potent killing of tumor cells by JANX007, with less potential for systemic side effects from cytokine release when compared to an unmasked T cell engager.”
At present, the company is in the process of opening additional study centres in Australia and the US.
JANX007 is said to be the first product candidate using the company’s TRACTr platform to be administered in human beings.
Janux Therapeutics president and CEO David Campbell said: “Our TRACTr platform is designed to generate tumor-specific immune responses to attack and kill tumors, without harming the patient’s healthy tissues.”
With this trial, the company aims to address critical unmet needs for cancer patients.
Janux is engaged in the development of a broad pipeline with lead TRACTr programmes that target PSMA, epidermal growth factor receptor, and trophoblast cell surface antigen 2.